**Case Report**

**Intravascular NK/T-cell lymphoma in the testis: a novel case report and review of the literature**

Hong Yu¹*, Jun Ye¹*, Haihui Sheng², Ji Zhang³, Hengjun Gao², Shunlong Li⁴, Chaofu Wang⁵

¹The Center for Translational Medicine, Taizhou People’s Hospital, Jiangsu Province, China; ²Shanghai Engineering Center for Molecular Medicine, National Engineering Center for Biochip at Shanghai, Shanghai, China; ³Department of Image, Taizhou People’s Hospital, Jiangsu Province, China; ⁴Department of General Surgery, Taizhou People’s Hospital, Jiangsu Province, China; ⁵Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. *Equal contributors.

Received May 2, 2016; Accepted May 21, 2016; Epub September 1, 2017; Published September 15, 2017

**Abstract:** Intravascular NK/T-cell lymphoma (IVNKTL) is an extremely rare type of lymphoma that frequently affects the skin. To date, only 14 cases of IVNKTL have been described. To the best of our knowledge, this is the first case report of IVNKTL in the testis.

**Keywords:** Intravascular NK/T-cell lymphoma, lymphoma, testis, diagnosis, differential diagnosis

**Introduction**

Intravascular lymphoma (IVL) is a rare and aggressive form of lymphoma characterized by neoplastic cells within blood vessels, and a predilection for the skin and brain. Most cases of IVL have a B-cell phenotype, but even rarer T-cell and NK-cell variants have been described [1]. Here we first report a case of IVNKTL presenting left testis swelling and review the literature.

**Case report**

A 58-year-old man presented to the hospital because of 3 months history of left testis swelling without pain, fever, urgency, frequent urination and dysuria in March, 2014. Physical examination showed swelling of the left testis. The results of radiological examination including magnetic resonance imaging (MRI) of the brain, neck, thorax and abdomen were unremarkable. Bone marrow biopsies and laboratory tests demonstrated no abnormalities. Surgical excision was recommended and the patient received a resection of the left testis. Postoperative pathological diagnosis was intravascular NK/T-cell lymphoma of the left testis. The patients received three courses of combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and was alive with no evidence of the disease after 22 months follow-up.

Grossly, the left testis measured 7 cm × 6 cm × 5 cm with smooth surface. The cut surface was soft to firm, fleshy, and gray to white with variable areas of yellow-red discoloration. Histologically, medium-sized to large-sized pleomorphic cells were confined within vessels in the interstitial tissue of testis. The pleomorphic cells had oval nuclei and a moderate amount of cytoplasm. Many mitotic figures were observed (Figure 1). Immunohistochemically, the neoplastic cells were positive for CD3, CD56, TIA-1, perforin, and granzyme B (GrB), and negative for CD20, CD79α, Pax-5, CD30, CD68, CD4, and CD8. The Ki-67 proliferation indices were approximately 100%. The vessels around the neoplastic cells were positive for CD34 and D2-40 (Figure 2). The intravascular neoplastic cells exhibited nuclear positivity for Epstein-Barr virus (EBER) (Figure 3). Overall findings supported a diagnosis of IVNKTL arising in the testis.

**Discussion**

IVNKTL is an extremely rare type of highly aggressive lymphoma. In 2003, Santucci [1]
first reported one case of IVNKTL presented with erythematous plaques on the trunk and thighs, leucopenia, and weight loss. To date, only 14 cases of IVNKTL have been reported in the English literature [1-9]. The clinicopathological features of the 15 cases including our case are summarized in Table 1, including 8 male and 7 female patients, with the mean age of 46.9 years old (range 18–72 years). Of the reported cases, the clinical course lasted from 2 months to 3 years, erythematous skin plaques or nodules on the trunk or limbs were observed in 14 cases, fever was observed in 5 cases, central nervous system (CNS) involvement was observed in 4 cases, and bone marrow involvement was observed in 2 cases. None of these 14 cases had nasal lymphoma. They were not related to nasal NK/T-cell lymphoma. The present patient only showed swelling of the left testis without skin or other organs involved, and to the best of our knowledge, this is the first reported case of IVNKTL confined to the testis. All 14 cases exhibited the same immunophenotype resembling that of nasal NK/T-cell lymphoma. Immunohistochemistry (IHC) showed that 14 cases were positive for CD3, CD56, and cytotoxic proteins including perforin, granzyme B and TIA-1, and negative for CD20 and CD79α. The Ki-67 proliferation indices were approximately 70-100% which denoted active proliferation of the neoplastic cells. In situ hybridization for EBER was positive in 13 cases. In our case, the immunohistochemical features and EBER in situ hybridization (ISH) results supported the diagnosis of IVNKTL. Among 14 previous reported cases, 1 case was without treatment, 2 cases of treatment was unknown, the other 11 cases were treated with CHOP or modified CHOP chemotherapy, and 2 cases among the 11 cases received stem cell transplantation (SCT) therapy meanwhile. Two cases were died at 14 and 15 days after diagnosis respectively because of the rapid progress of the disease. Eight cases were died during 4 to 17 months follow-up. Four cases were free of disease during 3 to 12 months follow-up. In the present case, the patient received three courses of CHOP chemotherapy and remained disease free after 22 months, and is undergoing follow-up.

Though extremely rare, the pathologic diagnosis of IVNKTL is often not difficult based on distinctive histopathologic, immunohistochemistry features, and EBV in situ hybridization analysis. However, IVNKTL should be distinguished from extranodal NK/T-cell lymphoma, nasal type (ENKTCL), aggressive NK-cell leukemia (ANKL), intravascular large B-cell lymphoma (IVLBCL), intravascular anaplastic large cell lymphoma (IVLACL), and metastatic carcinoma. Main clues for diagnosis and differential diagnosis including: IVNKTL tumor cells are confined within blood vessels. The size of the tumor cells are medium to large and are similar to lymphoblastoid cells in morphology. The immunophenotype of IVNKTL is similar to that of ENKTCL in which the neoplastic cells are positive for CD56, T-lineage (e.g., CD2 and CD3) markers and cytotoxic proteins including perforin, granzyme B, and TIA-1, whereas negative for B-lineage (e.g., CD20, CD79α, and Pax-5) markers. IVNKTL showed near 100% Ki-67 expression, indicating that proliferative activity of the tumor cells is very high. In situ hybridization for EBER is usually positive. It is needed to

![Figure 1](image1.png) Microscopic findings. A: Neoplastic cells arranged within vessels located in the interstitial tissue of testis (100 ×). B: Medium-sized to large-sized pleomorphic cells were confined within vessels and mitotic figures were easily found (400 ×).
Intravascular NK/T-cell lymphoma

Figure 2. IHC assay. A: The intravascular neoplastic cells were positive for CD3 (200 ×). B: The intravascular neoplastic cells were positive for CD56 (200 ×). C: The intravascular neoplastic cells were positive for TIA-1 (200 ×). D: Approximately 100% intravascular neoplastic cells were positive for Ki-67 (100 ×). E: The neoplastic cells confined within CD34+ vessel walls (200 ×).

Figure 3.ISH assay. The intravascular neoplastic cells were universally EBV positive as determined using ISH.

In summary, IVNKTL is an extremely rare, highly aggressive and EBV-associated lymphoma with a poor prognosis as a whole, which may be mainly due to multiorgan and multisystem involvement. The treatment of this disease is mainly based on CHOP or modified CHOP regimens, but the curative effect is far from satisfaction. In the present case, the tumor only involved the left testis without multiorgan or multisystem involvement. The patient received three courses of CHOP chemotherapy after surgery, and is remaining disease free for 22 months. However, the long-term prognosis of the patient remains to be further followed up and more cases should be documented for further understanding of this peculiar rare type of lymphoma and developing new effective methods for its treatment.

Acknowledgements

This work was supported by the Taizhou social development project Foundation, Jiangsu, China (grant No. TS028). The 333 project of scientific research project Foundation, Jiangsu, China (grant No. BRA2015224). The 12th five-year plan key project of science and technology, China (grant No. 2013ZX10002007).

Disclosure of conflict interest

None.

Address corresponding to: Dr. Chaofu Wang, Department of Pathology, Ruijin Hospital, Shanghai
### Table 1. Clinicopathological features of 15 cases of Intravascular NK/T-cell lymphoma

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age/Sex</th>
<th>Clinical features</th>
<th>IHC Positive</th>
<th>IHC Negative</th>
<th>EBER</th>
<th>Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>[1]</td>
<td>54/M</td>
<td>Erythematous plaques on trunk and thighs</td>
<td>CD3ε, CD56, TIA-1, GrB, CD30, Ki-67 (100%)</td>
<td>LMP1, CD4, CD8, CD20, CD79a, CD57, CD68, bcl-2</td>
<td>+</td>
<td>Five CHOP courses</td>
<td>17-month died of CNS involvement</td>
</tr>
<tr>
<td>[2]</td>
<td>41/M</td>
<td>Erythematous plaques on lower extremities</td>
<td>CD3ε, CD56, CD2, CD7, CD43, Bcl-2, TIA-1, Perforin</td>
<td>CD20, CD30, CD5, CD4, lysozyme, myeloperoxidase, CK</td>
<td>+</td>
<td>CHOP and SCT</td>
<td>12-month free of disease</td>
</tr>
<tr>
<td>[2]</td>
<td>47/F</td>
<td>Myalgia, arthralgia, weakness, fever, confusion, pancytopenia</td>
<td>CD2, CD3ε, CD7, CD56, TIA-1, GrB</td>
<td>CD20, CD4, CD5, CD8, CD57</td>
<td>-</td>
<td>Unknown</td>
<td>15-day died of multiple organ involvement including CNS</td>
</tr>
<tr>
<td>[3]</td>
<td>71/F</td>
<td>Erythematous nodules and patches on trunk and extremities</td>
<td>CD3ε, CD56, TIA-1, Ki-67 (99%)</td>
<td>CD20, CD4, CD5, CD8, CD10, CD30, bcl-2, LMP-1</td>
<td>+</td>
<td>No treatment</td>
<td>Alive 5-month after diagnosis</td>
</tr>
<tr>
<td>[4]</td>
<td>40/F</td>
<td>Erythematous skin lesions on whole body</td>
<td>LCA, CD3, CD56, TIA-1, GrB, CD45, Ki-67 (100%)</td>
<td>CD20, CD4, CD8, CD29</td>
<td>+</td>
<td>CODOX-M/IVAC</td>
<td>7-month free of disease</td>
</tr>
<tr>
<td>[5]</td>
<td>23/F</td>
<td>Abdomen erythema, leg edema, ileal ulcer, splenomegaly, fever</td>
<td>CD3ε, CD56, TIA-1, Ki-67 (100%)</td>
<td>CD20, CD79a, CD45RO</td>
<td>+</td>
<td>CHOP, ProMACE/CytaBOM, L-ASP/CY, hyper CVAD/MTX-Arac, related SCT</td>
<td>9-month died of aGVHD</td>
</tr>
<tr>
<td>[6]</td>
<td>63/M</td>
<td>Red-violaceous plaques on trunk and extremities</td>
<td>CD3ε, CD2, CD45RO, CD56, TIA-1</td>
<td>CD20, CD4, CD5, CD8, CD29</td>
<td>+</td>
<td>3 cycles of CHOP</td>
<td>6-month died after diagnosis</td>
</tr>
<tr>
<td>[7]</td>
<td>72/M</td>
<td>Erythematous plaques on trunk and extremities, secondary involvement of bone marrow and CNS</td>
<td>CD3ε, CD56, TIA-1, Ki-67 (70%)</td>
<td>CD20, CD4, CD29, CD8, CD30, CD34, CD54, MPO, Pankeratin</td>
<td>+</td>
<td>3 cycles of chlorambucil+urbasone</td>
<td>7-month died of spsis</td>
</tr>
<tr>
<td>[8]</td>
<td>38/F</td>
<td>Chest and back erythema, fever</td>
<td>CD3, GrB, CD56, Ki-67 (90%)</td>
<td>CD4, CD5, CD8, CD20, CD30, Pax-5, TdT</td>
<td>+</td>
<td>5 cycles of CHOP</td>
<td>13-month died of CNS involvement</td>
</tr>
<tr>
<td>[9]</td>
<td>45/M</td>
<td>Red macules on trunk and thigh</td>
<td>CD2, CD3ε, CD56, TIA-1 GrB, Perforin, Ki-67 (90-100%)</td>
<td>CD4, CD8, CD20, CD30</td>
<td>+</td>
<td>Unclear</td>
<td>2-week died of disease</td>
</tr>
<tr>
<td>[9]</td>
<td>52/F</td>
<td>Subcutaneous nodules in the left parotid region</td>
<td>CD2, CD3ε, CD56, TIA-1 GrB, Perforin, Ki-67 (90-100%)</td>
<td>CD4, CD8, CD20, CD30</td>
<td>+</td>
<td>6 cycles of CHOP</td>
<td>6-month died of disease</td>
</tr>
<tr>
<td>[9]</td>
<td>32/M</td>
<td>Patches on left thigh, fever</td>
<td>CD2, CD3ε, CD56, TIA-1 GrB, Perforin, Ki-67 (90-100%)</td>
<td>CD4, CD8, CD20, CD30</td>
<td>+</td>
<td>1 cycle of CHOP</td>
<td>4-month died of disease</td>
</tr>
<tr>
<td>[9]</td>
<td>18/F</td>
<td>Red macules and plaques on lower legs accompanying pain</td>
<td>CD2, CD3ε, CD56, TIA-1 GrB, Perforin, Ki-67 (90-100%)</td>
<td>CD4, CD8, CD20</td>
<td>+</td>
<td>CHOP</td>
<td>36-month free of disease</td>
</tr>
<tr>
<td>[9]</td>
<td>51/M</td>
<td>Abdominal pain and red patches on trunk and thigh, fever</td>
<td>CD2, CD3ε, CD56, TIA-1 GrB, Perforin, Ki-67 (90-100%)</td>
<td>CD4, CD8, CD20</td>
<td>+</td>
<td>CHOP+VP-16</td>
<td>6-month died of disease</td>
</tr>
<tr>
<td><strong>Our case</strong></td>
<td>57/M</td>
<td>Enlargement of left testis</td>
<td>CD3ε, CD56, TIA-1 GrB, Perforin, Ki-67 (approximately 100%)</td>
<td>CD20, CD79a, Pax-5, CD30, CD68, CD6, CD8</td>
<td>+</td>
<td>3 cycles of CHOP</td>
<td>22-month free of disease</td>
</tr>
</tbody>
</table>

CNS, Central nervous system; SCT, Stem cell transplantation; CODOX-M, Cyclophosphamide, vincristine, doxorubicin and methotrexate; VAC, Ifosfamide, mesna, etoposide and cytarabine; ProMACE/CytaBOM, Prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytosine arabinoside, bleomycin, vincristine, leucovorin; L-ASP, L-asparaginase; CY, Cyclophosphamide; hyper CVAD, Hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; MTX, Methotrexate; AraC, Cytosine arabinoside; aGVHD, Acute graft-versus-host disease.
Intravascular NK/T-cell lymphoma

Jiaotong University School of Medicine, Shanghai, China. E-mail: wangchaofu@126.com; Dr. Shun-long Li, Department of General Surgery, Taizhou People’s Hospital, Jiangsu Province, China. E-mail: 918968898@qq.com

References


